Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Corstasis Therapeutics’ Enbumyst Gains FDA Approval | Contract Pharma

What are you searching for?

Sign in
Breaking News

Corstasis Therapeutics’ Enbumyst Gains FDA Approval

Enbumyst is the first and only intranasal loop diuretic approved in the U.S., offering a self-administered alternative between oral and intravenous diuretics.

By: Rachel Klemovitch

Assistant Editor

Corstasis Therapeutics, a biopharmaceutical company providing outpatient therapeutic options for patients with cardiovascular and renal disease, announced that the U.S. Food and Drug Administration (FDA) has approved Enbumyst (bumetanide nasal spray).

Enbumyst is indicated to treat edema associated with congestive heart failure (CHF), hepatic and renal disease, including nephrotic syndrome in adults.

Enbumyst demonstrated rapid absorption and predictable diuretic response in clinical studies, with a similar effect on diuresis, natriuresis, and urinary potassium excretion when compared to IV bumetanide injection. This adds a new self-administered outpatient diuretic therapy, which may help bridge the gap between oral and IV diuretics for treating edema in patients with CHF, liver disease, and kidney disease. 

The FDA-approved Prescribing Information for Enbumyst does not include a boxed warning. 

Corstasis expects to launch Enbumyst in the U.S. in the fourth quarter of 2025, targeting cardiologists, nephrologists, hepatologists, outpatient heart failure clinics, and integrated delivery networks (IDNs). 

The company is also preparing a robust market access strategy, including real-world outcomes data and payer partnerships, to support rapid adoption and coverage.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics